IPCALAB Stock Overview
A pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, CIS, and Australasia.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
Ipca Laboratories Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,403.75 |
| 52 Week High | ₹1,460.00 |
| 52 Week Low | ₹878.00 |
| Beta | 0.24 |
| 11 Month Change | 2.79% |
| 3 Month Change | 19.60% |
| 1 Year Change | 56.02% |
| 33 Year Change | 8.14% |
| 5 Year Change | 196.60% |
| Change since IPO | 3,594.08% |
Recent News & Updates
Recent updates
Ipca Laboratories' (NSE:IPCALAB) Solid Earnings Have Been Accounted For Conservatively
Jun 07
Ipca Laboratories Limited (NSE:IPCALAB) Not Lagging Market On Growth Or Pricing
May 24Investors Interested In Ipca Laboratories Limited's (NSE:IPCALAB) Earnings
Feb 07Here's Why Ipca Laboratories (NSE:IPCALAB) Can Manage Its Debt Responsibly
Jan 09Is Ipca Laboratories (NSE:IPCALAB) A Risky Investment?
Aug 20Ipca Laboratories (NSE:IPCALAB) Has A Pretty Healthy Balance Sheet
Feb 28Here's Why Ipca Laboratories (NSE:IPCALAB) Can Manage Its Debt Responsibly
Sep 20Estimating The Intrinsic Value Of Ipca Laboratories Limited (NSE:IPCALAB)
Aug 31Is Ipca Laboratories (NSE:IPCALAB) A Risky Investment?
Jun 22Calculating The Fair Value Of Ipca Laboratories Limited (NSE:IPCALAB)
May 28Does Ipca Laboratories (NSE:IPCALAB) Have A Healthy Balance Sheet?
Mar 15These 4 Measures Indicate That Ipca Laboratories (NSE:IPCALAB) Is Using Debt Reasonably Well
Sep 20Is Now The Time To Put Ipca Laboratories (NSE:IPCALAB) On Your Watchlist?
Aug 09Does Ipca Laboratories (NSE:IPCALAB) Have A Healthy Balance Sheet?
Jun 08How Does Ipca Laboratories Limited (NSE:IPCALAB) Stand Up To These Simple Dividend Safety Checks?
Mar 26Do Ipca Laboratories's (NSE:IPCALAB) Earnings Warrant Your Attention?
Mar 13Trade Alert: The Compliance Officer Of Ipca Laboratories Limited (NSE:IPCALAB), Harish Kamath, Has Sold Some Shares Recently
Feb 28Ipca Laboratories Limited's (NSE:IPCALAB) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Feb 23Does Ipca Laboratories' (NSE:IPCALAB) CEO Salary Compare Well With Industry Peers?
Feb 11Could The Ipca Laboratories Limited (NSE:IPCALAB) Ownership Structure Tell Us Something Useful?
Jan 30The Ipca Laboratories (NSE:IPCALAB) Share Price Is Up 264% And Shareholders Are Boasting About It
Jan 15Ipca Laboratories (NSE:IPCALAB) Seems To Use Debt Rather Sparingly
Dec 31
Don't Ignore The Fact That This Insider Just Sold Some Shares In Ipca Laboratories Limited (NSE:IPCALAB)
Dec 16The Case For Ipca Laboratories Limited (NSE:IPCALAB): Could It Be A Nice Addition To Your Dividend Portfolio?
Dec 13This Insider Has Just Sold Shares In Ipca Laboratories Limited (NSE:IPCALAB)
Nov 28Shareholder Returns
| IPCALAB | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 1.7% | 0.5% | -1.0% |
| 1Y | 56.0% | 59.3% | 39.5% |
Return vs Industry: IPCALAB underperformed the Indian Pharmaceuticals industry which returned 59.3% over the past year.
Return vs Market: IPCALAB exceeded the Indian Market which returned 39.5% over the past year.
Price Volatility
| IPCALAB volatility | |
|---|---|
| IPCALAB Average Weekly Movement | 3.3% |
| Pharmaceuticals Industry Average Movement | 6.1% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in IN Market | 9.6% |
| 10% least volatile stocks in IN Market | 3.8% |
Stable Share Price: IPCALAB has not had significant price volatility in the past 3 months.
Volatility Over Time: IPCALAB's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1949 | 17,335 | Pranay Godha | www.ipca.com |
Ipca Laboratories Limited, a pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, CIS, and Australasia. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company also provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetes, dermatology, diabetology, emollients/protectives, fever, gastroenterology, hematology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology.
Ipca Laboratories Limited Fundamentals Summary
| IPCALAB fundamental statistics | |
|---|---|
| Market cap | ₹356.14b |
| Earnings (TTM) | ₹5.77b |
| Revenue (TTM) | ₹82.13b |
61.7x
P/E Ratio4.3x
P/S RatioIs IPCALAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IPCALAB income statement (TTM) | |
|---|---|
| Revenue | ₹82.13b |
| Cost of Revenue | ₹29.76b |
| Gross Profit | ₹52.38b |
| Other Expenses | ₹46.61b |
| Earnings | ₹5.77b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 22.73 |
| Gross Margin | 63.77% |
| Net Profit Margin | 7.02% |
| Debt/Equity Ratio | 18.6% |
How did IPCALAB perform over the long term?
See historical performance and comparison